- Positive study results from three-month formulation of Zoreline®, allowing progression to final clinical studies
- Pivotal trial will commence in Q1 2019, as previously expected
- Licensing agreement signed with UAE-based ITROM Pharmaceutical Group
Liège, Belgium, 21 December 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces positive results from its three-month PK Zoreline® study, and a licensing agreement for two products with UAE-based company ITROM Pharmaceutical Group (ITROM).